When Parachute Health founder and CEO David Gelbard’s father was discharged from the hospital following spine surgery, the hospital ordered a walker to assist him as he recovered. But for weeks, it didn’t arrive and Gelbard’s father subsequently fell, adding years to his rehabilitation.
RapidSOS, a five-year-old startup focused on updating emergency response systems with data-driven technology, has raised $16 million in funding from Highland Capital, Microsoft Ventures, and CSAA Insurance Group, according to a statement. Forté Ventures also contributed.
It's no secret that respiratory drugs make up a crowded field, and forthcoming generics will make the competition tougher still. AstraZeneca's Symbicort is no stranger to the fallout, either, what with payers pressing prices and new rivals grabbing share.
South Korean pharmaceutical firm Hanmi Pharmaceutical is expected to cease development of Olita, a lung cancer treatment, following its slow progress in clinical trials and cancellation of licensing deals with foreign drug makers.
Following a successful nine-month pilot, Boehringer Ingelheim and HealthPrize Technologies announced that the digital adherence support program RespiPoints will be expanded to any patient who is taking certain Boehringer Ingelheim medications, including some available in the Respimat inhaler.
Silvia Pfeiffer started Coviu with CSIRO colleague Nathan Oehlman in 2015, and it is now in use by 1100 healthcare professionals, with 160 of them paid subscribers to the software-as-a-service platform at $20 a month. More than 20,000 patients have been remotely consulted to date via the platform, which is browser-based and does not require a download.
NHS Digital’s sharing of non-clinical patient information with the Home Office has been branded “entirely inappropriate” by MPs, who say they are concerned about the body’s ability to act as a reliable steward of the data.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.